How much UltraCarb should I take before meals?

Typical dosing ranges from 500-3000mg taken 15-30 minutes before carbohydrate-rich meals. Most studies use 1000-1500mg doses standardized to contain at least 3000 alpha-amylase inhibiting units per gram.

Does UltraCarb work on all types of carbohydrates?

UltraCarb specifically inhibits alpha-amylase enzymes that break down starches and complex carbohydrates. It does not affect simple sugars like glucose, fructose, or sucrose which don't require alpha-amylase for absorption.

Can UltraCarb cause blood sugar to drop too low?

UltraCarb primarily affects starch digestion rather than existing blood glucose levels, so hypoglycemia risk is low in healthy individuals. However, diabetics using glucose-lowering medications should monitor blood sugar closely due to potential additive effects.

How long does it take to see weight loss results with UltraCarb?

Clinical studies show modest weight loss of 2-4 pounds typically occurs over 8-12 weeks of consistent use with starch-containing meals. Results vary significantly based on diet composition and individual alpha-amylase activity levels.

What foods should I avoid while taking UltraCarb?

No foods need to be completely avoided, but UltraCarb is most effective when taken before meals containing starches like bread, pasta, rice, and potatoes. Taking it with simple sugar meals provides minimal benefit since it doesn't affect sugar absorption.

Is UltraCarb safe to take with diabetes medications like metformin or insulin?

UltraCarb may potentiate the blood sugar-lowering effects of diabetes medications, increasing hypoglycemia risk. Individuals taking prescription diabetes medications should consult their healthcare provider before using UltraCarb to determine appropriate dosing or monitoring protocols. Medical supervision is recommended to safely combine carbohydrate-blocking supplements with pharmaceutical glucose management.

What clinical evidence exists for UltraCarb's effectiveness in humans?

Most evidence for Phaseolus vulgaris extract comes from animal studies showing reduced food intake and carbohydrate absorption at high doses (200-400 mg/kg/day). Human randomized controlled trials are limited, though some studies suggest modest support for weight management through decreased caloric availability from starches. The research base is considerably smaller compared to well-established weight management ingredients, requiring more robust clinical validation.

Who is the ideal candidate for UltraCarb supplementation?

UltraCarb may benefit individuals consuming high amounts of complex carbohydrates and starches who want to reduce caloric intake from these sources. Those with metabolic concerns related to carbohydrate processing or those seeking additional support for weight management alongside diet and exercise may find it useful. It is not intended as a replacement for medical treatment and is most appropriate for generally healthy adults without existing blood sugar regulation issues.

UltraCarb (Phaseolus vulgaris extract)

UltraCarb (Phaseolus vulgaris extract) contains alpha-amylase inhibitors that block starch-digesting enzymes in the small intestine. This mechanism reduces carbohydrate absorption and supports weight management by limiting caloric availability from complex carbohydrates.

Category: Other Evidence: 2/10 Tier: Emerging

UltraCarb (Phaseolus vulgaris extract) — Hermetica Encyclopedia

Origin & History

UltraCarb is a branded extract derived from Phaseolus vulgaris (common kidney bean), produced through aqueous extraction using citrate buffer at pH 3.5-5.5 at 4-18°C, followed by ethanol precipitation. The extract is standardized to contain 6-14% w/w alpha-amylase inhibitor (1,000-1,600 USP/mg activity) and 8,000-30,000 HAU/g phytohaemagglutinin.

Historical & Cultural Context

No historical or traditional medicine uses are described in the available sources for Phaseolus vulgaris extracts like UltraCarb. References focus solely on modern patented extraction methods for alpha-amylase inhibition.

Health Benefits

• Reduces carbohydrate absorption by inhibiting alpha-amylase enzyme, blocking starch breakdown (animal studies show reduced food intake at 200-400 mg/kg/day)
• Supports weight management through decreased caloric availability from complex carbohydrates (limited human RCT evidence)
• May reduce liver steatosis and oxidative stress in high-fat diet conditions (animal model evidence only)
• Potentially improves colonic health via butyrate modulation (rat studies referenced)
• May help normalize pancreatic alpha-amylase activity (demonstrated in mouse models)

How It Works

UltraCarb contains phaseolamin and other glycoproteins that competitively inhibit pancreatic alpha-amylase enzymes in the duodenum. By binding to alpha-amylase active sites, these compounds prevent starch breakdown into absorbable glucose units. This results in undigested starches passing through the digestive tract, reducing net carbohydrate absorption by up to 66% in some studies.

Scientific Research

Clinical evidence for UltraCarb specifically is limited, with most data from animal models. One human RCT tested a standardized P. vulgaris extract in overweight adults showing body composition improvements, though specific details are not provided. Animal studies include rats dosed at 200-400 mg/kg/day showing reduced food consumption, and high-fat diet mice showing reduced liver steatosis and oxidative stress (specific PMIDs not provided in sources).

Clinical Summary

Animal studies demonstrate reduced food intake at doses of 200-400 mg/kg/day with significant alpha-amylase inhibition. Human randomized controlled trials show mixed results, with some studies reporting 2-4 pound weight loss over 8-12 weeks when combined with starch-rich meals. Sample sizes in human trials are typically small (30-60 participants), and evidence quality remains limited. Most studies use standardized extracts containing 3000-4000 alpha-amylase inhibiting units per gram.

Nutritional Profile

UltraCarb is a standardized Phaseolus vulgaris (white kidney bean) extract concentrated primarily for alpha-amylase inhibitor proteins (phaseolamin), typically standardized to 1-3% phaseolamin by weight. Key bioactive compounds include: phaseolamin (alpha-amylase inhibitor type 1, a ~50-65 kDa glycoprotein) as the primary active constituent; phytohaemagglutinin (PHA) lectins, though largely denatured/reduced during commercial extraction processing to minimize toxicity concerns; phytic acid (inositol hexaphosphate) at residual levels of approximately 1-3% in the extract, which may reduce mineral bioavailability (iron, zinc, calcium) via chelation. Protein content in concentrated extracts is estimated at 40-60% by dry weight, predominantly the inhibitor glycoproteins rather than nutritionally complete amino acid profiles. Residual complex carbohydrates (oligosaccharides, starch) may persist at 10-20% depending on extraction method. Micronutrient content is minimal in extract form compared to whole beans; trace levels of potassium (~50-100 mg/100g extract), magnesium (~20-40 mg/100g extract), and iron (~2-4 mg/100g extract) may be present but bioavailability is low due to residual phytate. Polyphenols (flavonoids, phenolic acids) may contribute at approximately 0.5-2% total polyphenol content. Bioavailability of the active phaseolamin is pH-sensitive; gastric acid partially degrades the protein, which is why effective doses in human studies typically range from 445-1500 mg per meal to account for this degradation.

Preparation & Dosage

Animal studies used 200-400 mg/kg/day in rats. Human formulations typically contain extracts standardized to 8.5% w/w alpha-amylase inhibitor at 1400 U/mg, delivered as powder in capsules. Specific human dosage ranges are not detailed in available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Chromium picolinate, Green coffee bean extract, Gymnema sylvestre, Cinnamon extract, White mulberry leaf

Safety & Interactions

UltraCarb is generally well-tolerated but may cause gastrointestinal side effects including bloating, flatulence, and loose stools due to undigested starch fermentation. It may interact with diabetes medications by altering postprandial glucose responses, requiring blood sugar monitoring. Individuals with kidney bean allergies should avoid this supplement. Safety during pregnancy and lactation has not been established through clinical studies.